AVANIR PHARMACEUTICALS INC Inactive Instrument
Company Avanir Pharmaceuticals Inc
Equities
US05348P4019
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 2014 | Otsuka : Japan's Otsuka to buy Avanir for $3.5 billion ahead of patent cliff | RE |
| 2014 | NASDAQ OMX : names 14 stocks to test lower fee and rebate programme | RE |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Dan Dalton
CMP | Compliance Officer | - | 31/05/16 |
Kelly Parker
IRO | Public Communications Contact | - | 31/05/15 |
Aneta Ferguson
LAW | General Counsel | - | 31/12/14 |
Hisanori Maei
PRN | Corporate Officer/Principal | - | 12/01/15 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donald Hayden
CHM | Chairman | 68 | - |
Robert McQuade
BRD | Director/Board Member | 67 | - |
Thomas DesRosier
BRD | Director/Board Member | 69 | - |
Robert Sedor
BRD | Director/Board Member | - | 12/01/15 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 193,758,703 | 190,369,337 ( 98.25 %) | 0 | 98.25 % |
Company contact information
Sector
| 1st Jan change | Capi. | |
|---|---|---|
| +16.44% | 122B | |
| +18.94% | 114B | |
| +19.62% | 25.71B | |
| -25.37% | 19.02B | |
| -20.21% | 15.83B | |
| -20.20% | 15.32B | |
| -47.37% | 14.88B | |
| +59.91% | 14.82B | |
| +4.35% | 14.1B |
- Stock Market
- Equities
- Stock
- Company Avanir Pharmaceuticals Inc
